According to statistics, nearly 40 million American adults suffer from hearing loss, yet barely one in ten people who require hearing aids use them. Those who don’t use hearing aids but should should make it one of their New Year’s resolutions, according to a new study published today in The Lancet Healthy Longevity by Keck Medicine of USC.
Researchers found that the almost 25 per cent difference in mortality risk between regular hearing aid users and never-users remained steady, regardless of variables such as the degree of hearing loss (from mild to severe), age, ethnicity, income, education and other demographics; and medical history. There was no difference in mortality risk between non-regular users and non-users, indicating that occasional hearing aid use may not provide any life-extending benefit.
“We found that adults with hearing loss who regularly used hearing aids had a 24 per cent lower risk of mortality than those who never wore them,” said Janet Choi, MD, MPH, an otolaryngologist with Keck Medicine and lead researcher of the study. “These results are exciting because they suggest that hearing aids may play a protective role in people’s health and prevent early death.” Previous research has shown that untreated hearing loss can result in a reduced life span (as well as other poor outcomes such as social isolation, depression and dementia)
However, until now, there has been very little research examining if the use of hearing aids can reduce the risk of death. The study represents the most comprehensive analysis to date on the relationship between hearing loss, hearing aid use and mortality in the United States, according to Choi. Choi and her fellow researchers used data compiled by the National Health and Nutrition Examination Survey between 1999-2012 to identify almost 10,000 adults 20 years and older who had completed audiometry evaluations, a test used to measure hearing ability, and who filled out questionnaires about their hearing aid use. Researchers followed their mortality status over an average follow-up period of 10 years after their evaluations.